Connect Biopharma Holdings Ltd ordinary shares CNTB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.91
- Day Range
- $0.87–0.91
- 52-Week Range
- $0.85–3.82
- Bid/Ask
- $0.88 / $0.90
- Shares Outstanding
- 62.97M
- Market Cap
- $57.07M
- Volume/Avg
- 575,614 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 64
- Website
- https://www.connectbiopharm.com
Valuation
|
Metric
|
CNTB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.12 |
Price/Sales | 17.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNTB
|
|---|---|
Quick Ratio | 2.11 |
Current Ratio | 2.37 |
Interest Coverage | — |
Quick Ratio
CNTB
Profitability
|
Metric
|
CNTB
|
|---|---|
Return on Assets (Normalized) | −104.45% |
Return on Equity (Normalized) | −135.81% |
Return on Invested Capital (Normalized) | −136.88% |
Return on Assets
CNTB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$TZLSR$ | LOCK|#R&t | $127B | |||
| Moderna Inc
MRNA
| LOCK|%hdl>%$ | LOCK|%K | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|y$Q<lPS | LOCK|y!Vp | $81B | |||
| argenx SE ADR
ARGX
| LOCK|%c>N@T< | LOCK|rN | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|L>^d?># | LOCK|#V | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|K^@q!> | LOCK|!VLZ$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@%kTnq$ | LOCK|Nb@nZ | $27B | |||
| Incyte Corp
INCY
| LOCK|&n>#@?B | LOCK|&@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|V!Y@p@G | LOCK|#> | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Wh@MY& | LOCK|mKp | $14B |
United States